Navigation Links
Roches Arthritis Drug Successful in III Stage Trail

Roche Holding AG says that arthritis drug Actemra has proved successful in a phase III clinical study. Actemra helps relieve symptoms of rheumatoid arthritis in difficult-to-treat patients in a clinical study thus bringing it closer to regulatory approval.

The Radiate study was conducted over 24 weeks with 498 patients with difficult-to-treat RA. Actemra was given in combination with a standard treatment called methotrexate in patients who had an inadequate response to a relatively new type of drugs known as anti-tumor necrosis factor therapy, or anti-TNFs. The treatment showed a significant improvement in disease signs and symptoms.

Biologic Actemra (tocilizumab), a humanized monoclonal antibody works by a different mechanism than today's rheumatoid arthritis treatments. Actema is the first biologic to inhibit the interleukin-6, or Il-6, receptor. IL-6 is considered an important mediator of the acute inflammatory response.

Sufferers of rheumatoid arthritis, or RA, begin to experience progressive joint damage early in the disease. The disease differs from what is popularly known as arthritis, typically associated with age-related joint pain; RA is a far more serious inflammatory disease that leads to destruction of cartilage and bone, and can lead to disability.

Roche plans to file Actemra, developed by Japanese pharmaceutical company Chugai Pharmaceutical Co. which Roche controls, for regulatory approval in Europe and the U.S. by the end of 2007.

This is the third of five international late-stage trials that are investigating Actemra's efficacy and safety. Roche plans to release results from one more this year, while data from the fifth study will become available at a later date.


'"/>




Page: 1

Related medicine news :

1. Distinguished Scientist Award Conferred on University of Rochester Scientists for Work on Preventing Cavities
2. Another ray of hope for Arthritis Sufferers
3. Naked DNA Vaccination May Conquer Arthritis and Multiple Sclerosis
4. B Vitamin protects and lowers toxicity of Arthritis Drug
5. FDA Approves New Arthritis Drug, Bextra
6. Risk Of Developing Arthritis
7. Arthritis Drug May Cause Liver Damage
8. Arthritis drug can prolong life
9. New treatment for Rheumatoid Arthritis
10. Important cause of Arthritis
11. Personality Impacts Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica Scruggs ... for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs surgery, ... Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, MD, ...
(Date:6/25/2016)... ... , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors ... Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green ... hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train ...
(Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
(Date:6/24/2016)... Dallas, Texas (PRWEB) , ... June 24, 2016 ... ... 12th International Conference and Scientific Sessions in Dallas that it will receive two ... Announcement of the grants came as PHA marked its 25th anniversary by recognizing ...
(Date:6/24/2016)... ... ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for ... $12 an hour by 2020 and then adjusting it yearly to increase at the same ... wage, assure the wage floor does not erode again, and make future increases more predictable. ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
(Date:6/23/2016)...  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in ... . ... ... ... Astellas ...
(Date:6/23/2016)... June 23, 2016  Experian Health, the ... transforming the patient payment and care experience, ... new products and services that will enhance ... cycle offerings. These award-winning solutions will enable ... remain compliant in an ever-changing environment and ...
Breaking Medicine Technology: